| |
|
|
|
|
|
 |
| |
|
¾ÆÆ®·Îº¥Æ®¿¡¾î·Î¼Ö ATROVENT AERO.[Ipratropium Bromide]
|
|
ÀϹÝÀǾàǰ | »èÁ¦
|
|
|
| |
 |
¾Ë¸²: |
µå·°ÀÎÆ÷¿¡¼´Â ÀǾàǰ ÀÎÅÍ³Ý ÆÇ¸Å¸¦ ÇÏÁö ¾Ê½À´Ï´Ù. |
|
|
|
|
|
|
|
 |
|
|
|
|
|
|
|
|
|
|
À¯·áȸ¿ø °áÀç½Ã¿¡´Â º¸´Ù ´Ù¾çÇÑ ¾à¹°Á¤º¸¸¦
ÀÌ¿ëÇÏ½Ç ¼ö ÀÖ½À´Ï´Ù.
À¯·áÁ¤º¸¸ñ·ÏÀº Àü¹®È¸¿øÀ¸·Î
·Î±×ÀÎ ÇϽøé È®ÀÎ °¡´ÉÇÕ´Ï´Ù.
|
|
|
 | Çã°¡Á¤º¸ |
|
|
| Ç׸ñ |
³»¿ë |
û±¸ÄÚµå(KDÄÚµå) ºñ±Þ¿©Á¡°ËÄÚµå »óÇÑ±Ý¾× |
653500590[A07600521]
[º¸ÇèÄڵ忡 µû¸¥ ¾àǰ±âº»Á¤º¸ Á÷Á¢Á¶È¸]
\6,285 ¿ø/15ml/º´(2003.10.01)(Ãֽžడ)
[»óº´ÄÚµåÁ¶È¸]
[Áúº´ÄÚµåÁý ´Ù¿î·Îµå]
[¿ì¸®Áý°Ç°ÁÖÄ¡ÀÇ ¹Ù·Î°¡±â]
|
| ºü¸¥Á¶È¸ |
|
| Á¦Ç°¼º»ó |
Á¤·®½ÄºÐ¹«ÀåÄ¡°¡ ºÎÂøµÈ ¾Ë·ç¹Ì´½ ³»¾Ð¿ë±â¿¡ µç Å©¸²»ö Çöʾ×ÀÇ ¿¡¾î·Î¼ÖÁ¦
[Á¦ÇüÁ¤º¸ È®ÀÎ]
|
| Æ÷À塤À¯Åë´ÜÀ§ |
15ml
|
| Æ÷À塤ÄÚµå´ÜÀ§ |
| ¾àǰ±Ô°Ý |
´ÜÀ§ |
´ëÇ¥ÄÚµå |
Ç¥ÁØÄÚµå |
ºñ°í |
| 15¹Ð¸®¸®ÅÍ |
1 ¹ÙÀÌ¾Ë |
8806535005907 |
8806535005914 |
|
|
| ÁÖ¼ººÐÄÚµå |
177106CAE
[µ¿ÀÏÇÑ ÁÖ¼ººÐÄڵ带 °¡Áø ¿À¸®Áö³¯ ¶Ç´Â Á¦³×¸¯ ÀǾàǰ Á¶È¸]
|
| ´ëÇ¥ÄÚµå |
8806535005907 |
| º¸°ü¹æ¹ý |
±â¹Ð¿ë±â |
| ¾à¸®ÀÛ¿ë |
[Á¶È¸]
|
| È¿´ÉÈ¿°ú |
[ÀûÀÀÁõ º° °Ë»ö]
1.ÁÖÈ¿´É È¿°ú
´ÙÀ½ ÁúȯÀÇ ±âµµÆó¼â¼º Àå¾Ö¿¡ ÀÇÇÑ È£Èí°ï¶õ µî ¿©·¯Áõ»óÀÇ ¿ÏÈ : ±â°üÁöõ½Ä, ¸¸¼º±â°üÁö¿°, Æó±âÁ¾
[Drugbank ÀÇ ¼ººÐÁ¤º¸¿¶÷] [Ipratropium]
|
| ¿ë¹ý¿ë·® |
* Àý´ë ÀÓÀǺ¹¿ëÇÏÁö ¸¶½Ã°í ¹Ýµå½Ã ÀÇ»ç ¶Ç´Â ¾à»ç¿Í »ó´ãÇϽñ⠹ٶø´Ï´Ù.
[󹿾à¾î]
[ÁÖ¼ººÐÄÚµå:177104CAE ¿¡ µû¸¥ ½É»çÁöħ¿¶÷]
¼ºÀÎ : 1ȸ 1-2¹ø(ºê·ÒÈÀÌÇÁ¶óÆ®·ÎÇÇ¿ò¹«¼ö¹°·Î¼ 20-40ug)¾¿ 1ÀÏ 3-4ȸ ºÐ¹«ÇÑ´Ù. ¿¬·É, Áõ»ó¿¡ µû¶ó ÀûÀýÈ÷ Áõ°¨ÇÑ´Ù.
[Á¦Çüº°º¹¾àÁöµµ]
|
| ±Ý±â |
- ¾ÆÆ®·ÎÇÉ ¶Ç´Â ±× À¯µµÃ¼¿¡ °ú¹ÎÁõ ȯÀÚ
- ³ì³»Àå ȯÀÚ
- Àü¸³¼± ºñ´ëÁõ ȯÀÚ
|
| ÀÌ»ó¹ÝÀÀ |
- Á¤½Å½Å°æ°è :
¶§¶§·Î µÎÅë, ÁøÀü, µå¹°°Ô µÎÁß°¨, ¾îÁö·¯¿ò, ÇÇ·Î, ºÒ¸é, °¨°¢ÀÌ»ó, Á¹À½, ÇùÁ¶Àå¾Ö(Coordination difficulty)µîÀÌ ³ªÅ¸³¯ ¼ö ÀÖ´Ù.
¼Òȱâ°è : ¶§¶§·Î ±¸¿ª, µå¹°°Ô ±¸Åä, »óº¹ºÎÅë, º¯ºñµîÀÌ ³ªÅ¸³¯ ¼ö ÀÖ´Ù.
¼øÈ¯±â°è : ¶§¶§·Î ½É°èÇ×ÁøÀÌ ³ªÅ¸³¯ ¼ö ÀÖ´Ù.
ÇǺΠ: µå¹°°Ô ÇǺιßÁø, °¡·Á¿ò, µÎµå·¯±â, È«Á¶, Å»¸ð°¡ ³ªÅ¸³¯ ¼ö ÀÖ´Ù.
±¸°: ¶§¶§·Î ±¸°¥, µå¹°°Ô °í¹Ì, ÇôÀÇ ¸¶ºñ, ÇôÀÇ ±Õ¿, ÀεκÒÄè°¨, ÀÎµÎÆó¼â°¨, ÀεÎÅë, ±¸³»¿°µîÀÌ ³ªÅ¸³¯ ¼ö ÀÖ´Ù.
±âŸ : µå¹°°Ô ½É¿ÍºÎÅë, °¡·¡·Î ÀÎÇØ ¼ûÂ÷´Â °ÍÀÌ ¾Ç鵃 ¼ö ÀÖÀ¸¸ç µå¹°°Ô ±âµµÀÚ±Ø Áõ»ó, ±âħ, ¹è´¢Àå¾Ö, ½®¸ñ¼Ò¸®, ¸Þ½º²¨¿ò, ºÎÁ¾, ÈäÅëÀÌ ³ªÅ¸³¯ ¼ö ÀÖ´Ù.
|
| »óÈ£ÀÛ¿ë |
ÀÌ ¾àÀº ¸¸¼º Æó¼â¼º ÆóÁúȯ Ä¡·á¿¡ »ç¿ëµÇ´Â ±³°¨½Å°æÈïºÐ¼º ±â°üÁöÈ®ÀåÁ¦, Å©»êƾ°è ¾à¹°, ½ºÅ×·ÎÀ̵åÁ¦, Å©·Î¸ð±Û¸®Å©»ê³ªÆ®·ýµî°ú º´¿ëÅõ¿©ÇÒ ¼ö ÀÖ´Ù. |
| ÀӺο¡ ´ëÇÑ Åõ¿© |
[ÀӺαݱ⠼ººÐ Á¶È¸]
ÀÓ½ÅÁßÀÇ Åõ¿©¿¡ ´ëÇÑ ¾ÈÀü¼ºÀÌ È®¸³µÇ¾î ÀÖÁö ¾ÊÀ¸¹Ç·Î ÀӺΠ¶Ç´Â ÀÓ½ÅÇϰí ÀÖÀ» °¡´É¼ºÀÌ ÀÖ´Â ºÎÀο¡´Â Ä¡·á»óÀÇ À¯ÀͼºÀÌ À§Ç輺À» »óȸÇÑ´Ù°í ÆÇ´ÙµÇ´Â °æ¿ì¿¡¸¸ Åõ¿©ÇÑ´Ù.
|
| ¼öÀ¯ºÎ¿¡ ´ëÇÑ Åõ¿© |
ÀÌ ¾àÀÌ ¸ðÀ¯·Î ºÎÅÍ ºÐºñµÇ´ÂÁö´Â ¾Ë·ÁÁöÁö ¾Ê¾ÒÀ¸³ª, ¸¹Àº ¾àµéÀÌ ¸ðÀ¯·Î ºÐºñµÇ¹Ç·Î ¼öÀ¯ºÎ¿¡ Åõ¿©ÇÒ °æ¿ì¿¡´Â ÁÖÀÇÇÑ´Ù. |
| ¼Ò¾Æ¿¡ ´ëÇÑ Åõ¿© |
ÀϹÝÀûÀ¸·Î °í·ÉÀÚ´Â »ý¸®±â´ÉÀÌ ÀúÇϵǾî ÀÖÀ¸¹Ç·Î ¿ë·® ¹× Åõ¿©°£°Ý¿¡ À¯ÀÇÇÏ´Â µî ÁÖÀÇÇÑ´Ù. |
| Àû¿ë»óÀÇ ÁÖÀÇ |
»êµ¿ÀÛ¿ëÀÌ ÀÖÀ¸¹Ç·Î ´«À» ÇâÇØ ºÐ»çÇÏÁö ¾Ê´Â´Ù. |
| º¸°ü ¹× Ãë±Þ»óÀÇ ÁÖÀÇ |
±â¹Ð¿ë±â |
| ±âŸ |
- ¿ë±â´Â ´Ù ¾´ ÈÄ¿¡ ºÒ ¼Ó¿¡ ¹ö¸®Áö ¾Ê´Â´Ù.
- ¾î´ðÅÍ´Â Áï½Ã µû¶æÇÑ ¹°·Î ÃæºÐÈ÷ ´Û¾Æ û°áÇÏ°Ô º¸Á¸½ÃŲ´Ù.
- ºÐ¹«±â(³×ºÒ¶óÀÌÀú)·Î ÀÌ ¾à°ú Ȳ»ê»ìºÎŸ¸ôÀ» º´¿ëÇÑ È¯ÀÚ¿¡¼ ÈíÀÔ¾×ÀÌ ´«¿¡ µé¾î°£ °æ¿ì ±Þ¼º Æó¼â¿ì°¢Çü³ì³»ÀåÀÌ ³ªÅ¸³µ´Ù´Â º¸°í°¡ ÀÖ´Ù.
|
| Related FDA Approved Drug |
|
|
|
 | Á¤º¸¿ä¾à |
|
|
|
µå·°ÀÎÆ÷ ÀǾàǰ ¿ä¾à/»ó¼¼Á¤º¸
|
|
 | ÄÚµå ¹× ºÐ·ùÁ¤º¸ |
|
|
| |
|
 | Á¦Ç°Á¤º¸ |
|
|
|
|
 | º¹¾àÁ¤º¸ |
|
|
| Ç׸ñ |
³»¿ë |
| LACTmed ¹Ù·Î°¡±â |
[¹Ù·Î°¡±â]
|
| ¾à¸®ÀÛ¿ë |
À¯·áÁ¤º¸ÀÔ´Ï´Ù.
|
| Ãà¾àº¹¾àÁöµµ |
À¯·áÁ¤º¸ÀÔ´Ï´Ù.
|
| º¹¾àÁöµµ |
À¯·áÁ¤º¸ÀÔ´Ï´Ù.
|
| ÀӺο¡´ëÇÑÅõ¿© |
| * |
ÀüüÀӽŠ±â°£º°·Î ¿©·¯µî±ÞÀÌ Á¸ÀçÇÒ ¼ö ÀÖÀ¸¸ç °¡Àå À§Çèµµ°¡ ³ôÀº Á¤º¸¸¸ º¸¿©Áý´Ï´Ù. ´Ü, º¹ÇÕÁ¦ÀÇ °æ¿ì ¸ðµç º¹ÇÕÁ¦¼ººÐ¿¡ ´ëÇÑ ÀÓºÎÅõ¿©µî±ÞÀÌ Ç¥½ÃµÈ°ÍÀº Àý´ë ¾Æ´Ï¸ç Ç¥½ÃµÈ°ÍÁß¿¡ °¡Àå À§Çèµµ°¡ ³ôÀº Á¤º¸¸¸ ³ªÅ¸³³´Ï´Ù.
|
|
|   |
 FDA : Bµî±Þ
|
|
| * |
»ó±â ÀÓºÎÅõ¿©¿¡ ´ëÇÑ Á¤º¸´Â Àü»êó¸® µÇ¸é¼ ÀÔ·Â ¿À·ù °¡´É¼ºÀÌ Á¸ÀçÇÕ´Ï´Ù. ¿À·ù °¡´É¼ºÀ» ÃÖ¼ÒÈÇϱâ À§ÇÏ¿© ¸¹Àº ³ë·ÂÀ» ±â¿ïÀ̰í ÀÖÀ¸³ª, ±× Á¤È®¼º¿¡ ´ëÇÏ¿© È®½ÅÀ» µå¸± ¼ö ¾ø½À´Ï´Ù. ÀÌ¿¡ ´ëÇØ ȸ»ç´Â Ã¥ÀÓÀ» ÁöÁö ¾Ê½À´Ï´Ù.
|
| * |
¹Ýµå½Ã °ø½Å·Â ÀÖ´Â ¹®ÇåÀ» ´Ù½Ã Çѹø Âü°í ÇϽñ⠹ٶó¸ç ÀÇ»ç ¶Ç´Â ¾à»çÀÇ ÆÇ´Ü¿¡ µû¶ó Åõ¿©¿©ºÎ°¡ °áÁ¤µÇ¾î¾ß ÇÕ´Ï´Ù.
|
|
|
| Pharmacokinetics |
À¯·áÁ¤º¸ÀÔ´Ï´Ù.
|
| º´¿ë±Ý±â ¹× ¿¬·É´ë±Ý±â ±Ù°ÅÁ¶È¸ |
[º´¿ë±Ý±â ¹× ¿¬·É´ë±Ý±â ±Ù°ÅÁ¶È¸]
|
| º¹¾à¶óº§ |
| À̹ÌÁö |
º¹¾à¼³¸í |
 |
º¯ºñ°¡ »ý±æ¼ö ÀÖ½À´Ï´Ù. |
|
 |
¾îÁö·¯¿òÀÌ ÀÖÀ»¼ö ÀÖ½À´Ï´Ù. |
|
|
| * |
º¹¾àÀ̹ÌÁö´Â ¸ðµç º¹¾àÁöµµ »çÇ×À» Ç¥½ÃÇѰÍÀº ¾Æ´Ï¸ç, Ãß°¡ÀûÀ¸·Î ¾÷µ¥ÀÌÆ®µÇ°Å³ª ¼öÁ¤µÉ ¼ö ÀÖ½À´Ï´Ù. |
| * |
º¹¾àÀ̹ÌÁöÀÇ Ç¥½Ã¿©ºÎ´Â ½ÇÁ¦ ¾à¹°º¹¿ë½Ã Á߿䵵¿¡ µû¸¥°ÍÀº ¾Æ´Ï¸ç ´Ü¼øÈ÷ Çã°¡Á¤º¸»ó Ű¿öµå¸¦ ±âÁØÀ¸·Î µî·ÏµÇ¾ú½À´Ï´Ù. |
| * |
±ÍÇϰ¡ º¹¾àÀ̹ÌÁö Á¤º¸¸¦ ½Å·ÚÇÔÀº ÀüÀûÀ¸·Î ±ÍÇÏÀÇ Ã¥ÀÓÀÔ´Ï´Ù. µå·°ÀÎÆ÷´Â ÀÌ¿¡ ´ëÇÑ ¾î¶°ÇÑ º¸Áõµµ ÇÏÁö ¾Ê½À´Ï´Ù. |
|
|
| Á¦Çüº° º¹¾àÁöµµ |
[¿¡¾î·Î¼Ö] |
| º¸°ü»ó ÁÖÀÇ |
|
| Á¶Á¦½Ã ÁÖÀÇ |
|
|
|
 | ½É»çÁ¤º¸ |
|
|
|
|
 | ÇмúÁ¤º¸ |
|
|
| Ç׸ñ |
³»¿ë |
| DUR (ÀǾàǰ»ç¿ëÆò°¡) |
º´¿ë±Ý±â :
°í½ÃµÈ º´¿ë±Ý±â ³»¿ëÀº ¾ø½À´Ï´Ù.
[»óÈ£ÀÛ¿ë/º´¿ë±Ý±â°Ë»ö]
¿¬·É´ë±Ý±â :
°í½ÃµÈ ¿¬·É±Ý±â ³»¿ëÀº ¾ø½À´Ï´Ù.
[¿¬·É´ë±Ý±â»ó¼¼°Ë»ö]
|
| Mechanism of Action |
Ipratropium¿¡ ´ëÇÑ Mechanism_Of_Action Á¤º¸ Ipratropium bromide is an anticholinergic agent. It blocks muscarinic cholinergic receptors, without specificity for subtypes, resulting in a decrease in the formation of cyclic guanosine monophosphate (cGMP). Most likely due to actions of cGMP on intracellular calcium, this results in decreased contractility of smooth muscle.
|
| Pharmacology |
Ipratropium¿¡ ´ëÇÑ Pharmacology Á¤º¸ Ipratropium bromide, a synthetic ammonium compound structurally similar to atropine, is used as a bronchodilator in the management of cholinergic-mediated bronchospasm associated with chronic obstructive pulmonary disease and in the treatment of rhinorrhea associated with the common cold or with allergic or nonallergic seasonal rhinitis.
|
| Metabolism |
Ipratropium¿¡ ´ëÇÑ Metabolism Á¤º¸ # Phase_1_Metabolizing_Enzyme:Cytochrome P450 2D6 (CYP2D6)Cytochrome P450 3A4 (CYP3A4)
|
| Protein Binding |
Ipratropium¿¡ ´ëÇÑ ´Ü¹é°áÇÕ Á¤º¸ Minimally (0 to 9% in vitro) bound to plasma albumin and a1-acid glycoproteins
|
| Half-life |
Ipratropium¿¡ ´ëÇÑ ¹Ý°¨±â Á¤º¸ Approximately 2 hours
|
| Absorption |
Ipratropium¿¡ ´ëÇÑ Absorption Á¤º¸ Inhalation (local)-minimal; Nasal-rapid and minimal
|
| Pharmacokinetics |
Ipratropium BromideÀÇ ¾à¹°µ¿·ÂÇÐÀÚ·á
- ±â°üÁöÈ®ÀåÈ¿°ú ¹ßÇö½Ã°£ : 1-3ºÐ
- ÃÖ´ëÈ¿°ú ¹ßÇö½Ã°£ : 1.5-2 ½Ã°£ À̳»
- ÀÛ¿ëÁö¼Ó½Ã°£ : 4-6 ½Ã°£±îÁö
- Èí¼ö : ÆóÀÇ Ç¥¸éÀ̳ª À§Àå°üÀ¸·ÎºÎÅÍ Àü½Å¼øÈ¯À¸·ÎÀÇ Èí¼ö´Â °ÅÀÇ ¾øÀ½.
- ºÐÆ÷ : ÈíÀÔ : ¿ë·®ÀÇ 15%°¡ Çϱ⵵¿¡ µµ´Þ
|
| Biotransformation |
Ipratropium¿¡ ´ëÇÑ Biotransformation Á¤º¸ Hepatic
|
| Toxicity |
Ipratropium¿¡ ´ëÇÑ Toxicity Á¤º¸ LD50=1001mg/kg (orally in mice)
|
| Drug Interactions |
Ipratropium¿¡ ´ëÇÑ Drug_Interactions Á¤º¸ Not Available
|
CYP450 Drug Interaction |
[CYP450 TableÁ÷Á¢Á¶È¸]
|
| Food Interaction |
Ipratropium¿¡ ´ëÇÑ Food Interaction Á¤º¸ Not Available
|
| Drug Target |
[Drug Target]
|
| Description |
Ipratropium¿¡ ´ëÇÑ Description Á¤º¸ A muscarinic antagonist structurally related to atropine but often considered safer and more effective for inhalation use. It is used for various bronchial disorders, in rhinitis, and as an antiarrhythmic. [PubChem]
|
| Dosage Form |
Ipratropium¿¡ ´ëÇÑ Dosage_Form Á¤º¸ Aerosol, metered NasalAerosol, metered Respiratory (inhalation)Liquid NasalLiquid Respiratory (inhalation)Solution NasalSolution Respiratory (inhalation)Spray, metered Nasal
|
| Drug Category |
Ipratropium¿¡ ´ëÇÑ Drug_Category Á¤º¸ AntimuscarinicsAntispasmodicsBronchodilator AgentsCholinergic Antagonists
|
| Smiles String Canonical |
Ipratropium¿¡ ´ëÇÑ Smiles_String_canonical Á¤º¸ CC(C)[N+]1(C)C2CCC1CC(C2)OC(=O)C(CO)C1=CC=CC=C1
|
| Smiles String Isomeric |
Ipratropium¿¡ ´ëÇÑ Smiles_String_isomeric Á¤º¸ CC(C)[N+]1(C)[C@@H]2CC[C@@H]1CC(C2)OC(=O)C(CO)C1=CC=CC=C1
|
| InChI Identifier |
Ipratropium¿¡ ´ëÇÑ InChI_Identifier Á¤º¸ InChI=1/C20H30NO3/c1-14(2)21(3)16-9-10-17(21)12-18(11-16)24-20(23)19(13-22)15-7-5-4-6-8-15/h4-8,14,16-19,22H,9-13H2,1-3H3/q+1/t16-,17-,18?,19?,21?/m1/s1
|
| Chemical IUPAC Name |
Ipratropium¿¡ ´ëÇÑ Chemical_IUPAC_Name Á¤º¸ [(1R,5R)-8-methyl-8-propan-2-yl-8-azoniabicyclo[3.2.1]octan-3-yl] 3-hydroxy-2-phenylpropanoate
|
|
|
 | »ç¿ëÀÚÄÁÅÙÃ÷ |
|
|
|
|
|
-
ÃÖ±ÙÁ¤º¸¼öÁ¤ÀÏ 2021-12-09
-
º» ¼öÁ¤ÀÏ Á¤º¸´Â Çã°¡Á¤º¸ ÀÌ¿ÜÀÇ ±âŸÁ¤º¸ ¼öÁ¤ÀÏÀ» ÀǹÌÇϹǷÎ, Çã°¡Á¤º¸¼öÁ¤ÀÏÀº º»¹®¿¡ Ç¥±âµÈ ³¯Â¥¸¦ ÂüÁ¶ÇϽñ⠹ٶø´Ï´Ù.
|
|
¾Ë¸² |
»ó¼¼Á¤º¸´Â ½ÄǰÀǾàǰ¾ÈÀüóÀÇ Á¦Ç°Çã°¡»çÇ×À» Åä´ë·Î ÀÛ¼ºµÇ¾úÀ¸¸ç ¿ä¾àÁ¤º¸´Â »ó¼¼Á¤º¸ ¹× ±âŸ¹®ÇåÀ» ±â¹ÝÀ¸·Î µå·°ÀÎÆ÷¿¡¼ ÆíÁýÇÑ ³»¿ëÀÔ´Ï´Ù. Á¦Ç°Çã°¡»çÇ×ÀÇ ¸ñÂ÷¿Í ´Ù¼Ò »óÀÌÇÒ ¼ö ÀÖ½À´Ï´Ù. |
|
°æ°í |
µå·°ÀÎÆ÷ ÀǾàÇмúÁ¤º¸´Â ½ÄǰÀǾàǰ¾ÈÀüóÀÇ Á¦Ç°Çã°¡»çÇ×, Çмú¹®Çå, Á¦¾àȸ»ç Á¦°øÁ¤º¸ µîÀ» ±Ù°Å·Î ÀÛ¼ºµÈ Âü°í Á¤º¸ÀÔ´Ï´Ù.
Á¤º¸ÀÇ Á¤È®¼ºÀ» À§ÇØ ³ë·ÂÇϰí ÀÖÀ¸³ª ÆíÁý»óÀÇ ¿À·ù, Çã°¡»çÇ× º¯°æ, Ãß°¡ÀûÀÎ Çмú¿¬±¸ ¶Ç´Â Àӻ󿬱¸ ¹ßÇ¥ µîÀ¸·Î ÀÎÇØ ¹ß»ýÇÏ´Â ¹®Á¦¿¡ ´ëÇØ µå·°ÀÎÆ÷´Â
Ã¥ÀÓÀ» ÁöÁö ¾Ê½À´Ï´Ù. ÀÚ¼¼ÇÑ ³»¿ëÀº ¡°Ã¥ÀÓÀÇ ÇÑ°è ¹× ¹ýÀû°íÁö¡±¸¦ ÂüÁ¶ÇØ ÁֽʽÿÀ.
¹Ýµå½Ã Á¦Á¶¡¤¼öÀÔ»ç, ÆÇ¸Å»ç, ÀÇ»ç, ¾à»ç¿¡°Ô ÃÖÁ¾ÀûÀ¸·Î È®ÀÎÇϽñ⠹ٶø´Ï´Ù.
ÀüÈ: 02-3486-1061 ¤Ó À̸ÞÀÏ: webmaster@druginfo.co.kr
|
|
¾Æ·¡ÀÇ ³»¿ëÀ» Æ÷ÇÔÇÑ Àüü µ¥ÀÌÅ͸¦ º¸½Ã·Á¸é
¿©±â·Î À̵¿ÇϽñ⠹ٶø´Ï´Ù.
º´¿ë±Ý±â ¹× ƯÁ¤¿¬·É´ë ±Ý±â ¼ººÐ
[ÀǾàǰº´¿ë/¿¬·É´ë±Ý±â °í½Ã±Ù°Å·Î ¹Ù·Î°¡±â] Á¦¸ñ ¾øÀ½
2008³â 8¿ù 1ÀÏ ¾à°¡ÈÀÏ»ó 8¿ù´Þ ½Å±ÔµîÀç ¹× »èÁ¦µÇ´Â ǰ¸ñ Æ÷ÇÔÇÑ º´¿ë¿¬·É ±Ý±â ǰ¸ñ¸®½ºÆ® ±âÁØ
1. ÇöÀç °Ë»öÇÑ Á¦Ç°¿¡ ´ëÇÑ º´¿ë±Ý±â Á¦Ç° Á¸Àç¿©ºÎ ¹× °Ë»ö
ÇöÀç ÀÌÁ¦Ç°¿¡ ´ëÇÑ º´¿ë±Ý±â¿¡ ÇØ´çÇϴ û±¸Äڵ庰 Á¦Ç°³»¿ª °øÁö³»¿ëÀÌ ¾ø½À´Ï´Ù
2. ¿¬·É´ë±Ý±â Á¸Àç¿©ºÎ
ÇöÀç ÀÌÁ¦Ç°¿¡ ´ëÇÑ ¿¬·É±Ý±â¿¡ ÇØ´çÇϴ û±¸Äڵ庰 °øÁö³»¿ëÀÌ ¾ø½À´Ï´Ù
|
|
|
|